NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a pre-existing royalty interest in Nuvalent’s neladalkib and zidesamtinib from an undisclosed third party for up to $315 million. Neladalkib and zidesamtinib are next-generation tyrosine kinase inhibitors (TKIs). Neladalkib is in development for patients with ALK mutation-positive non-small cell lung cancer... Read More

NEW YORK and SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Denali Therapeutics, Inc. (Nasdaq: DNLI) today announced a $275 million synthetic royalty funding agreement based on future net sales of tividenofusp alfa. Tividenofusp alfa is Denali’s lead investigational TransportVehicleTM-enabled enzyme replacement therapy for the treatment of mucopolysaccharidosis type II... Read More

NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of December: Citi’s 2025 Global Healthcare Conference on Tuesday, December 2 at 3:15 p.m. ET Evercore’s 8 th Annual Healthcare Conference on Wednesday, December 3 at 3:50 p.m. ET The webcast will be accessible from Royalty Pharma’s “Events” page... Read More

Portfolio Receipts growth of 11% to $814 million; Royalty Receipts growth of 11% Net cash provided by operating activities of $703 million Raised full year 2025 guidance: Portfolio Receipts expected to be $3,200 to $3,250 million NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2025 and raised full year 2025 guidance for Portfolio... Read More

NEW YORK and CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in Alnylam’s AMVUTTRA from funds managed by Blackstone Life Sciences (“Blackstone”) for $310 million. The royalty interest being sold stems from Blackstone’s 2020 financing collaboration with Alnylam , in which Blackstone invested to support AMVUTTRA’s pivotal Phase 3... Read More

NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on December 10, 2025, to shareholders of record at the close of business on November 14, 2025. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical... Read More

NEW YORK, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2025 financial results on Wednesday, November 5, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s website at... Read More

NEW YORK, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that the independent directors of the Board have unanimously appointed Dr. Ted W. Love, an independent director since 2020, as Lead Independent Director. Dr. Love will continue to Chair the Nominating and Corporate Governance Committee. “I am delighted to welcome Ted to the key role of Lead Independent Director,” said Pablo... Read More

NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at Bernstein’s 2 nd Annual Healthcare Forum on Tuesday, September 23, 2025 at 2:50 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/ . The webcast will also be archived for a minimum of thirty days. About Royalty... Read More

On track to deliver Portfolio Receipts of $4.7 billion or more by 2030, significantly ahead of consensus Goal to achieve at least mid-teens average annual total shareholder return over next 5 years with significant upside potential from recognition for Royalty Pharma’s platform value Investments since 2020 on track to deliver mid-teens unlevered IRR, ahead of target Achieved 15% Return on Invested Capital (ROIC) and 21%... Read More

First of its kind report offers insight from over 110 biopharma executives into the benefits of royalties, current market dynamics and outlook for royalty market expansion Royalties have become integral to biopharma’s diversified capital landscape driven by attractive cost of capital, flexibility and positive investor perception NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced... Read More

NEW YORK, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Morgan Stanley 23 rd Annual Global Healthcare Conference on Tuesday, September 9, 2025 at 3:20 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/ . The webcast will also be archived for a minimum of thirty... Read More

NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $2.0 billion of senior unsecured notes, comprised of the following (collectively, the “Notes”): $600 million of 4.450% Notes due 2031 (the “2031 Notes”); $900 million of 5.200% Notes due 2035 (the “2035 Notes”); and $500 million of 5.950% Notes due 2055 (the “2055 Notes”). The Notes will be... Read More

Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease Additional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related Disease NEW YORK and WALTHAM, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Zenas BioPharma, Inc. (Nasdaq: ZBIO) today... Read More

Imdelltra is a first-in-class immunotherapy for the treatment of extensive-stage small cell lung cancer (ES-SCLC) marketed by Amgen Royalty Pharma to pay $885 million upfront; BeOne Medicines to retain a $65 million option to sell additional portion of its royalty NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in Amgen’s Imdelltra, a... Read More

NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that Henry Fernandez, its Lead Independent Director, has stepped down from its Board of Directors, effective August 13, 2025. Mr. Fernandez joined the Royalty Pharma Board of Directors in July 2020 and was unanimously appointed as Lead Independent Director in March 2021. “We are tremendously grateful for Henry's contributions to... Read More

Portfolio Receipts growth of 20% to $727 million; Royalty Receipts growth of 11% Net cash provided by operating activities of $364 million Raised full year 2025 guidance: Portfolio Receipts expected to be $3,050 to $3,150 million NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2025 and raised full year 2025 guidance for Portfolio... Read More

NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on September 10, 2025, to shareholders of record at the close of business on August 15, 2025. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical... Read More

Strengthens Board of Directors with appointment of two new independent members, increasing independent representation to greater than 90% Underscores Royalty Pharma’s commitment to enhanced corporate governance following acquisition of its external manager NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Carole Ho and Elizabeth (Bess) Weatherman to its Board of... Read More

NEW YORK, July 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2025 financial results on Wednesday, August 6, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s website at... Read More

Up to $1.25 billion ($250 million upfront) of synthetic royalty funding and up to $750 million in secured debt Innovative partnership enables Revolution Medicines to retain control over pipeline development and global commercialization of daraxonrasib Highlights Royalty Pharma’s unique ability to provide capital at scale to help leading companies achieve their strategic goals Daraxonrasib, in Phase 3 development for... Read More

NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Goldman Sachs 46 th Annual Global Healthcare Conference on Tuesday, June 10, 2025 at 2:00 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/ . The webcast will also be archived for a minimum of thirty days.... Read More

NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has successfully closed the acquisition of its external manager, RP Management, LLC (“RP Management”). The acquisition received overwhelming support from Royalty Pharma’s shareholders, with 99.9% of votes cast in favor of the transaction. “The completion of the internalization marks an exciting new chapter for Royalty... Read More

NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May: BofA Securities 2025 Healthcare Conference on Wednesday, May 14 at 5:20 p.m. ET / 2:20 p.m. PT RBC Capital Markets 2025 Global Healthcare Conference on Tuesday, May 20 at 4:05 p.m. ET The webcasts will be accessible from Royalty Pharma’s... Read More

Received overwhelming shareholder approval with 99.9% of votes cast in favor Simplified structure benefits shareholders through strengthened shareholder alignment, enhanced governance, significant cash savings and increased economic return on investments Significant annual cash savings of greater than $100 million in 2026 growing to over $175 million in 2030, with cumulative savings of more than $1.6 billion over ten years... Read More

Portfolio Receipts growth of 17% to $839 million; Royalty Receipts growth of 12% Net cash provided by operating activities of $596 million Raised full year 2025 guidance: Portfolio Receipts expected to be $2,975 to $3,125 million NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts.... Read More

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ordinary share. The dividend will be paid on June 10, 2025, to shareholders of record at the close of business on May 16, 2025. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties... Read More

NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s website at... Read More

NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Vlad Coric, M.D. to the company’s Board of Directors, effective immediately. Vlad Coric is the Chairman and Chief Executive Officer of Biohaven, a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience,... Read More

NEW YORK, March 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will host an Investor Day in New York City on Thursday, September 11, 2025, starting at 8:30 a.m. ET. Royalty Pharma senior executives will provide an update on the company’s plans to drive shareholder value creation through leveraging its unique business model and capabilities in the large and growing market for funding... Read More

NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 45 th Annual Health Care Conference on March 4, 2025 at 2:30 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/ . The webcast will also be archived for a minimum of thirty days. About Royalty Pharma... Read More

NEW YORK, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Biogen to provide research and development (R&D) funding of up to $250 million for litifilimab, a first-in-class investigational drug candidate in Phase 3 with demonstrated proof-of-concept in both systemic lupus erythematosus (SLE) and cutaneous lupus erythematosus (CLE). “We are excited... Read More

Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024 Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 Net cash provided by operating activities of $743 million in Q4 2024 and $2,769 million for FY 2024 Full year 2025 guidance: Portfolio Receipts expected to be $2,900 to $3,050 million excluding future transactions NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq:... Read More

Total proceeds of $530 million on $300 million original 2022 investment Proceeds strengthen balance sheet and provide added flexibility to pursue disciplined capital allocation strategy, including significant share repurchases and royalty acquisitions NEW YORK, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the closing of a transaction to monetize the remaining fixed payments on the... Read More

NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2024 financial results on Tuesday, February 11, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s website... Read More

2024 Portfolio Receipts expected to be approximately $2,800 million, at the upper end of guidance range Exciting development-stage pipeline with potential for peak royalties of >$1.2 billion; multiple key upcoming events, including Phase 3 results for pelacarsen Royalty Pharma to benfit from new product launches in 2025, including Servier’s Voranigo, Bristol Myers Squibb’s Cobenfy, Ascendis’ Yorvipath, Syndax and Incyte’s... Read More

Royalty Pharma plc to become an integrated company by acquiring its external manager, RP Management, LLC Significant annual cash savings of greater than $100 million in 2026 growing to over $175 million in 2030, with cumulative savings of more than $1.6 billion over ten years Simplified structure to benefit shareholders through strengthened shareholder alignment, enhanced governance and increased economic return on... Read More

NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2025 of $0.22 per Class A ordinary share, reflecting a 5% increase in the company’s quarterly dividend over the previous quarter’s dividend. The dividend will be paid on March 10, 2025 to shareholders of record at the close of business on February 21, 2025.... Read More

NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of December: 7 th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3 at 12:55 p.m. ET Citi’s 2024 Global Healthcare Conference on Wednesday, December 4 at 1:45 p.m. ET The webcasts will be accessible from Royalty Pharma’s “Events”... Read More

Royalty Pharma inaugural Prize for Impact in Healthcare awarded to Michael Milken, the founder of the Milken Institute, Faster Cures & the Prostate Cancer Foundation The Prize includes a charitable donation to further fund medical research NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the inaugural Royalty Pharma Prize for Impact in Healthcare, which honors individuals or... Read More

RYTELO™ (imetelstat) is FDA approved for the treatment of low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia Transaction increases Royalty Pharma’s synthetic royalty funding to $925 million in 2024, highlighting the significant opportunity for this attractive funding modality NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will acquire... Read More

Portfolio Receipts growth of 15% to $735 million; Royalty Receipts growth of 15% Net cash provided by operating activities of $704 million Capital Deployment of approximately $1.2 billion Raising full year 2024 guidance: Portfolio Receipts expected to be $2,750 to $2,800 million NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2024 and... Read More

Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenib Expected to fund Syndax through profitability; proforma cash approaching $800 million as of June 30 NEW YORK and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Syndax Pharmaceuticals (Nasdaq: SNDX) today announced that Royalty Pharma has entered into a $350 million... Read More

NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2024 financial results on Wednesday, November 6, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s website at... Read More

NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2024 of $0.21 per Class A ordinary share. The dividend will be paid on December 10, 2024, to shareholders of record at the close of business on November 15, 2024. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical... Read More

NEW YORK and COPENHAGEN, Denmark, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Ascendis Pharma A/S (Nasdaq: ASND) today announced that Royalty Pharma and Ascendis Pharma Bone Diseases A/S, a wholly-owned subsidiary of Ascendis Pharma A/S, has entered into a $150 million capped synthetic royalty funding agreement based on U.S. net sales of Yorvipath. “We are pleased to again partner with Royalty... Read More

NEW YORK, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at Morgan Stanley’s 22 nd Annual Health Care Conference on September 5, 2024 at 9:15 a.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/ . The webcast will also be archived for a minimum of thirty days. About... Read More

Portfolio Receipts growth of 12% to $608 million; Royalty Receipts growth of 11% Net cash provided by operating activities of $658 million Raising full year 2024 guidance: Portfolio Receipts expected to be $2,700 to $2,775 million NEW YORK, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the second quarter of 2024 and raised full year 2024 guidance for Portfolio... Read More

NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Molly Sawaya as Executive Vice President, Head of Human Capital. Molly joins Royalty Pharma from Hudson Bay Capital, where she was a Managing Director and Head of Colleague Experience, responsible for designing and delivering the firm’s Human Resources (HR) agenda, including onboarding, colleague engagement,... Read More

NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s website at... Read More

NEW YORK, July 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2024 of $0.21 per Class A ordinary share. The dividend will be paid on September 13, 2024, to shareholders of record at the close of business on August 16, 2024. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical... Read More

NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Goldman Sachs 45 th Annual Global Healthcare Conference on June 11, 2024 at 2:00 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/ . The webcast will also be archived for a minimum of thirty... Read More

NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) announced today that it has priced an offering of $1.5 billion of senior unsecured notes, comprised of the following (collectively, the “Notes”): $500 million of 5.150% Notes due 2029 (the “2029 Notes”); $500 million of 5.400% Notes due 2034 (the “2034 Notes”); and $500 million of 5.900% Notes due 2054 (the “2054 Notes”). The Notes will be... Read More

Vorasidenib, if approved, would be the first targeted therapy in IDH-mutant glioma, a progressive and incurable brain tumor Pivotal Phase 3 clinical study of vorasidenib demonstrated unprecedented efficacy and tolerability; vorasidenib granted priority review with PDUFA date of August 20, 2024 Royalty Pharma projects greater than $1 billion in peak sales annually for vorasidenib in the U.S.; potential to generate royalties... Read More

Deal provides Cytokinetics with diversified access to capital as company advances its specialty cardiology franchise NEW YORK and SOUTH SAN FRANCISCO, Calif., May 22, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Cytokinetics, Incorporated (Nasdaq: CYTK) today announced they have entered into a strategic funding collaboration providing capital to support the commercialization of aficamten and advance the... Read More

NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May: RBC Capital Markets 2024 Global Healthcare Conference on Tuesday, May 14 at 9:00 a.m. ET BofA Securities 2024 Healthcare Conference on Wednesday, May 15 at 6:00 p.m. ET / 3:00 p.m. PT The webcasts will be accessible from Royalty Pharma’s... Read More

Royalty Receipts growth of 14% driving Portfolio Receipts of $717 million Net cash provided by operating activities of $665 million Full year 2024 guidance confirmed: Portfolio Receipts expected to be $2,600 to $2,700 million Commitment to grow dividend by mid-single digit percentage annually NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of... Read More

Frexalimab is in Phase 3 development by Sanofi in multiple sclerosis with multi-blockbuster potential in a wide range of immune-mediated diseases Expands Royalty Pharma’s development-stage portfolio to 15 therapies with the combined potential to generate significantly greater than $1 billion in annual peak royalties Royalty Pharma to highlight the strength of its development-stage pipeline on its first quarter of 2024... Read More

NEW YORK, April 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s website at... Read More

NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2024 of $0.21 per Class A ordinary share. The dividend will be paid on June 14, 2024, to shareholders of record at the close of business on May 17, 2024. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties... Read More

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 44 th Annual Health Care Conference on March 5, 2024 at 10:30 a.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/ . The webcast will also be archived for a minimum of thirty days. About Royalty Pharma... Read More

Portfolio Receipts of $736 million in Q4 2023 and $3,049 million for FY 2023 Net cash provided by operating activities of $773 million in Q4 2023 and $2,988 million for FY 2023 Announced transactions of up to $4.0 billion in 2023 Full year 2024 guidance: Portfolio Receipts of $2,600 to $2,700 million (reflecting royalty receipts growth of 5% to 9% year/year) excluding future transactions NEW YORK, Feb. 15, 2024 (GLOBE... Read More

NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2023 financial results on Thursday, February 15, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s website... Read More

NEW YORK, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2024 of $0.21 per Class A share, reflecting a 5% increase in the company’s quarterly dividend over the previous quarter’s dividend. The dividend will be paid on March 15, 2024 to shareholders of record at the close of business on February 16, 2024. About... Read More

2023 Portfolio Receipts expected to be approximately $3,050 million, exceeding the upper end of guidance range Announced transactions of $13 billion since 2020 expected to add approximately $1.2 billion to Portfolio Receipts in 2025 NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today provided an update on its business performance, including recent key accomplishments, and the full year 2023... Read More

NEW YORK, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 6 th Annual HealthCONx Conference on November 28, 2023 at 3:00 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page and can be accessed directly by clicking here . The webcast will also be archived for a minimum of thirty days. About... Read More

Royalty Pharma to provide R&D funding support of up to $125 million for the development of olanzapine LAI (TEV-‘749), a long-acting subcutaneous injectable olanzapine for schizophrenia Phase 3 data expected in the second half of 2024 NEW YORK and TEL AVIV, Israel, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries... Read More

Net cash provided by operating activities (GAAP) of $574 million and Adjusted Cash Receipts ( 1) (non-GAAP) of $637 million Announced transactions of up to $3.8 billion year-to-date, including $2.1 billion in upfront payments Raising 2023 guidance: Adjusted Cash Receipts ( 1) (non-GAAP) expected to be $2,950 to $3,000 million NEW YORK, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported... Read More

Royalty Pharma purchases a portion of royalties on Roche’s Evrysdi for $1.0 billion upfront PTC Therapeutics has option to sell rest of royalty for up to $500 million; Royalty Pharma has option to buy half of rest of royalty for up to $250 million Transaction expected to enhance long-term Adjusted Cash Receipts growth (non-GAAP) Royalty Pharma to host conference call today, Thursday, October 19 at 9:00am EDT NEW YORK, Oct.... Read More

NEW YORK, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2023 financial results on Wednesday, November 8, 2023 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s website at... Read More

NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Eric Schneider as Senior Vice President, Chief Technology Officer. Eric will also join Royalty Pharma’s Senior Leadership Committee. Eric joins Royalty Pharma from Verisk, a global leader in data-driven analytic insights and solutions, where he was a Senior Vice President, Chief Data Officer and Chief Technology... Read More

P roceeds to support continued development and commercialization of Endocrine Rare Disease products and general corporate purposes NEW YORK and COPENHAGEN, Denmark, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Ascendis Pharma A/S (Nasdaq: ASND) today announced that Royalty Pharma has entered into a $150 million capped synthetic royalty funding agreement with Ascendis based on U.S. net Skytrofa... Read More

NEW YORK, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of September: Citi’s 18 th Annual BioPharma Conference on Wednesday, September 6 at 11:20 a.m. ET Morgan Stanley’s 21 st Annual Global Healthcare Conference on Tuesday, September 12 at 12:55 p.m. ET The webcasts will be accessible from Royalty... Read More

Royalty Pharma to pay Ferring $300 million upfront and a potential $200 million milestone payment in exchange for royalties on the sales of Ferring’s intravesical gene therapy Adstiladrin ® (nadofaragene firadenovec-vncg) Transaction provides Ferring with significant non-dilutive capital to support the manufacturing capacity expansion, commercialization and further clinical development of Adstiladrin for bladder cancer... Read More

Net cash provided by operating activities (GAAP) of $608 million and Adjusted Cash Receipts ( 1) (non-GAAP) of $545 million Announced transactions of up to $1.7 billion year-to-date, including $659 million in upfront payments Raising 2023 guidance: Adjusted Cash Receipts ( 1) (non-GAAP) expected to be $2,900 to $2,975 million NEW YORK, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported... Read More

NEW YORK, July 18, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2023 financial results on Tuesday, August 8, 2023 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s website at... Read More

NEW YORK, July 17, 2023 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2023 of $0.20 per Class A ordinary share. The dividend will be paid on September 15, 2023, to shareholders of record at the close of business on August 18, 2023. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical... Read More

NEW YORK, June 07, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the Goldman Sachs 44 th Annual Global Healthcare Conference on June 13, 2023 at 5:00 p.m. ET / 2:00 p.m. PT. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and-events/events . The webcast will also be archived for a minimum of... Read More

Net cash provided by operating activities (GAAP) of $1,034 million and Adjusted Cash Receipts ( 1) (non-GAAP) of $1,131 million Announced transactions of up to $1.6 billion in Q1 2023, including $600 million in upfront payments Reaffirmed 2023 Adjusted Cash Receipts ( 1) guidance (increased in March) of $2,850 to $2,950 million NEW YORK, May 09, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported... Read More

NEW YORK, May 03, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to present at the BofA Securities 2023 Health Care Conference on Wednesday, May 10, 2023 at 5:20 p.m. ET / 2:20 p.m. PT. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and-events/events . The webcast will also be archived for a minimum of thirty... Read More

NEW YORK, April 17, 2023 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2023 of $0.20 per Class A ordinary share. The dividend will be paid on June 15, 2023, to shareholders of record at the close of business on May 19, 2023. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties... Read More

NEW YORK, April 13, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2023 financial results on Tuesday, May 9, 2023 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s website at... Read More

Royalty Pharma’s founder and Chief Executive Officer, Pablo Legorreta, has also indicated that he intends to purchase up to an additional $50 million of the company’s Class A ordinary shares NEW YORK, March 27, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that the company’s Board of Directors has authorized the repurchase of up to $1.0 billion of the company’s Class A ordinary shares. Royalty... Read More

Royalty Pharma has acquired an interest in PureTech’s royalty in Karuna Therapeutics’ KarXT; Royalty Pharma and PureTech will share in royalties above certain annual sales thresholds PureTech retains its current equity stake in Karuna in addition to milestone payments and 20% of sublicense revenues due to PureTech Transaction provides further non-dilutive capital for PureTech’s growing and rapidly advancing Wholly Owned... Read More

Royalty Pharma now expects 2023 Adjusted Cash Receipts ( 1) (non-GAAP) to be between $2,850 million and $2,950 million, excluding contributions from future transactions NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has received a $475 million accelerated milestone payment from Pfizer, following the U.S. Food and Drug Administration (FDA) approval of Zavzpret... Read More

NEW YORK, March 01, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Ashwin Pai, M.D. as Executive Vice President, Investments. Ashwin will join Royalty Pharma in April 2023, and will report to Chris Hite, Executive Vice President and Vice Chairman. Ashwin joins Royalty Pharma from Morgan Stanley where he was a Managing Director and Head of West Coast Biotechnology Investment... Read More

Net cash provided by operating activities (GAAP) of $570 million and Adjusted Cash Receipts ( 1) (non-GAAP) of $1,064 million in Q4 2022 Announced transactions of u p to $3.5 billion in 2022, including $2.0 billion i n upfront payments Full year 2023 guidance: Adjusted Cash Receipts ( 1) (non-GAAP) of $2,375 to $2,475 million; excludes potential zavegepant approval milestone of $475 million NEW YORK, Feb. 15, 2023 (GLOBE... Read More

NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the months of February and March: SVB Securities Global Biopharma Conference on Thursday, February 16 at 10:40 a.m. ET Cowen 43rd Annual Health Care Conference on Tuesday, March 7 at 11:10 a.m. ET The webcasts will be accessible from Royalty Pharma’s... Read More

NEW YORK, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2022 financial results on Wednesday, February 15, 2023 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m. Eastern Time that day. Conference Call Information Please visit the “Investors” page of the company’s... Read More

2022 Net cash provided by operating activities (GAAP) expected to be approximately $2,140 million to $2,150 million; 2022 Adjusted Cash Receipts (1) (non-GAAP) expected to be approximately $2,785 million to $2,790 million, towards the upper end of guidance range Announced transactions of $10 billion since 2020 expected to add ~$1 billion to Adjusted Cash Receipts (1) (non-GAAP) in 2025 NEW YORK, Jan. 09, 2023 (GLOBE... Read More

Royalty Pharma to acquire an interest in SPINRAZA® and pelacarsen royalties – Ionis retains majority of royalties and all milestones from Novartis for pelacarsen Royalty Pharma to pay Ionis $500 million upfront and up to $625 million in milestones Agreement enables Ionis to achieve commercial readiness for multiple late-stage programs and advance its innovative pipeline of genetic medicines NEW YORK and CARLSBAD, Calif.,... Read More

NEW YORK, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2023 of $0.20 per Class A share, reflecting a 5.3% increase in the company’s quarterly dividend over the previous quarter’s dividend. The dividend will be paid on March 15, 2023 to shareholders of record at the close of business on February 16, 2023. “We... Read More

NEW YORK, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will present at the 41 st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 11:15 a.m. ET / 8:15 a.m. PT. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/news-and-events/events . The webcast will also be archived for a minimum of thirty days.... Read More

Promotions of Sara Klymkowsky, Brienne Kugler and Alessandra Sassun NEW YORK, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the expansion of its senior leadership team. This expansion highlights Royalty Pharma’s success in developing a talented, diverse and experienced leadership team responsible for formulating and executing on its mission to accelerate innovation and transform patient... Read More